PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- MolecuLight Corp. , the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, announces the publication of peer-reviewed clinical research highlighting the transformative power of MolecuLight in healing more pressure injuries with fewer infection complications among 167 Medicare beneficiaries across 55 US-based Long Term Care and Skilled Nursing Facilities.
Published by Martha R. Kelso and colleagues, the article entitled "Improving Wound Healing and Infection Control in Long-term Care with Bacterial Fluorescence Imaging" is featured in the latest edition of Advances in Skin & Wound Care journal. The authors report an impressive improvement in pressure injury outcomes among incredibly complex and healing-challenged patients.
This is a testament to the power of MolecuLight technology, which continues to prove its effectiveness even in the most challenging patient base. When comparing the outcomes of patients that were treated per standard of care approach alone with those in which MolecuLight real-time fluorescence was integrated into that care, those in the MolecuLight-imaged group saw 71% more wounds healed by 12 weeks, healed 28% faster, and were 1.8 times more likely to heal their wound by 12-weeks.
The researchers also investigated the incidence of severe infection complications including cellulitis, osteomyelitis, gangrene, sepsis, and wound-related hospitalization, reporting .